Search

Your search keyword '"Shoushtari, A"' showing total 3,382 results
Start Over Author "Shoushtari, A"
3,382 results on '"Shoushtari, A"'

351. Deciphering radiological stable disease to immune checkpoint inhibitors

Author

J, Luo, S, Wu, H, Rizvi, Q, Zhang, J V, Egger, J C, Osorio, A J, Schoenfeld, A J, Plodkowski, M S, Ginsberg, M K, Callahan, C, Maher, A N, Shoushtari, M A, Postow, M H, Voss, R R, Kotecha, A, Gupta, R, Raja, M G, Kris, and M D, Hellmann

Subjects
Antineoplastic Agents, Immunological, Lung Neoplasms, Oncology, Carcinoma, Non-Small-Cell Lung, Biomarkers, Tumor, Humans, Hematology, Immune Checkpoint Inhibitors
Abstract

'Stable disease (SD)' as per RECIST is a common but ambiguous outcome in patients receiving immune checkpoint inhibitors (ICIs). This study aimed to characterize SD and identify the subset of patients with SD who are benefiting from treatment. Understanding SD would facilitate drug development and improve precision in correlative research.A systematic review was carried out to characterize SD in ICI trials. SD and objective response were compared to proliferation index using The Cancer Genome Atlas gene expression data. To identify a subgroup of SD with outcomes mirroring responders, we examined a discovery cohort of non-small-cell lung cancer (NSCLC). Serial cutpoints of two variables, % best overall response and progression-free survival (PFS), were tested to define a subgroup of patients with SD with similar survival as responders. Results were then tested in external validation cohorts.Among trials of ICIs (59 studies, 14 280 patients), SD ranged from 16% to 42% in different tumor types and was associated with disease-specific proliferation index (ρ = -0.75, P = 0.03), a proxy of tumor kinetics, rather than relative response to ICIs. In a discovery cohort of NSCLC [1220 patients, 313 (26%) with SD to ICIs], PFS ranged widely in SD (0.2-49 months, median 4.9 months). The subset with PFS6 months and no tumor growth mirrored partial response (PR) minor (overall survival hazard ratio 1.0) and was proposed as the definition of SD responder. This definition was confirmed in two validation cohorts from trials of NSCLC treated with durvalumab and found to apply in tumor types treated with immunotherapy in which depth and duration of benefit were correlated.RECIST-defined SD to immunotherapy is common, heterogeneous, and may largely reflect tumor growth rate rather than ICI response. In patients with NSCLC and SD to ICIs, PFS6 months and no tumor growth may be considered 'SD responders'. This definition may improve the efficiency of and insight derivable from clinical and translational research.

Published
2022

352. Pulmonary Function Tests in Thunderstorm-associated Respiratory Symptoms: A Cross-sectional Study.

Author

Shoushtari, Maryam Haddadzadeh, Afrakhteh, Sakineh, Borsi, Seyed Hamid, Raji, Hanieh, and Idani, Esmail

Subjects
*ASTHMA risk factors, *LIGHTNING strike injuries, *CROSS-sectional method, *METHACHOLINE chloride, *COMPARATIVE studies, *T-test (Statistics), *OBSTRUCTIVE lung diseases, *BRONCHIAL provocation tests, *DESCRIPTIVE statistics, *CHI-squared test, *PULMONARY function tests, *SPIROMETRY, *DATA analysis software, *SYMPTOM burden, *SYMPTOMS, *DISEASE complications
Abstract

Background: Epidemic thunderstorm asthma is an observed increase in cases of acute bronchospasm following thunderstorms. This study aimed to compare the frequency of obstructive airway disease or bronchial hyperresponsiveness in subjects with thunderstorm-associated respiratory symptoms with subjects with similar symptoms presented at other times. Methods: A cross-sectional study from June to November of 2013 was conducted on subjects with thunderstorm-associated respiratory symptoms living in Ahvaz City, Iran. Thunderstorm-associated subjects were presented with asthmatic symptoms in thunderstorms, and other patients presented with similar symptoms at other times. Baseline spirometry was performed on patients to examine the presence of obstructive airway disease. In all patients with normal spirometry, a provocation test was applied. A comparison of qualitative and quantitative variables was made using the Chi-square and independent t test, respectively. All analyses were carried out using SPSS Statistics Version 22. A P value less than 0.05 was considered statistically significant. Results: Out of 584 subjects, 300 and 284 participants were in thunderstorm-associated and non-thunderstorm-associated groups, respectively. After the final analysis, 87 (30.6%) and 89 (33.3%) of the thunderstorm-associated subjects and non-thunderstorm-associated group, respectively, had pieces of evidence of airflow limitation (P=0.27). Among the patients with normal spirometry, 161 (81.72%) of the thunderstorm-associated patients and 100 (56.17%) patients of the non-thunderstorm-associated symptoms group had a positive methacholine challenge test result (P<0.001). Conclusion: Most of the patients with thunderstorm-associated respiratory symptoms had no obvious evidence of airflow limitation in spirometry. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

353. One-step and Rapid Identification of SARS-CoV-2 using Real-Time Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP).

Author

Shoushtari, Mohammad, Zeinoddini, Mehdi, Fathi, Javad, Alikhani, Hani Keshavarz, and Shiekhi, Fatemeh

Subjects
*PREVENTION of infectious disease transmission, *RISK assessment, *PROTEINS, *COST effectiveness, *COVID-19 testing, *SCIENTIFIC observation, *PLASMIDS, *REVERSE transcriptase polymerase chain reaction, *INFLUENZA, *DESCRIPTIVE statistics, *EXPERIMENTAL design, *RNA, *WORLD health, *PATHOLOGICAL laboratories, *COMPARATIVE studies, *COVID-19, *LOOP-mediated isothermal amplification, *SENSITIVITY & specificity (Statistics)
Abstract

Background: SARS-CoV-2 as the cause of novel coronavirus disease (COVID-19) is a member of the family Coronaviridea that has generated an emerging global health concern. Controlling and preventing the spread of the disease requires a simple, portable, and rapid diagnostic method. Today, a standard method for detecting SARS-CoV-2 is quantitative real-time reverse transcription PCR, which is time-consuming and needs an advanced device. The aim of this study was to evaluate a faster and more cost-effective field-based testing method at the point of risk. We utilized a one-step RT-LAMP assay and developed, for the first time, a simple and rapid screening detection assay targeting the Envelope (E) gene, using specific primers. Methods: For this, the total RNA was extracted from respiratory samples of COVID-19 infected patients and applied to one-step a RT-LAMP reaction. The LAMP products were visualized using green fluorescence (SYBR Green I). Sensitivity testing was conducted using different concentrations of the designed recombinant plasmid (TA-E) as positive control constructs. Additionally, selectivity testing was performed using the influenza H1N1 genome. Finally, the results were compared using with conventional real time RT-PCR. Results: It was shown that the RT-LAMP assay has a sensitivity of approximately 15 ng for the E gene of SARS-CoV-2 when using extracted total RNA. Additionally, a sensitivity of 112 pg was achieved when using an artificially prepared TA-E plasmid. Accordingly, for the detection of SARS-CoV-2 infection, the RT-LAMP had high sensitivity and specificity and also could be an alternative method for real-time RT-PCR. Conclusion: Overall, this method can be used as a portable, rapid, and easy method for detecting SARS-CoV-2 in the field and clinical laboratories. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

354. Resiliency and dyeability of environmentally friendly polypropylene/poly (trimethylene terephthalate)/nanoclay blend nanocomposite fibers.

Author

Habibolah Zargar, Mohammad Reza, Ehsani, Morteza, Ebrahimzade, Amin, Nobre, Marcos A. L., Mousavi Shoushtari, Seyed Ahmad, and Khonakdar, Hossein Ali

Abstract

An environmentally friendly free-carrier procedure was used to prepare polypropylene/poly(trimethylene terephthalate)/nanoclay (PP/PTT/NC) blend nanocomposite fibers. Adding NC to the PP/PTT blend diminished the average diameter of PTT from 140 mm for the PP/PTT blend to 85 mm for the blend containing 1 phr nanoclay. Moreover, adding PTT and NC did not affect the mechanical properties of PP significantly. The crystallinity of the PP blend increased by almost 15% when 10 wt.% PTT and 1 phr NC were added. Molten neat PP and its blends and blend nanocomposites showed a typical pseudo-plastic flow behavior. Also, the storage modulus of all samples increased nearly linearly in the frequency range of 1 to 1000 1/sec. About 20% advancement in resiliency and 40% enhancement in dyeability were obtained. The dye uptake ability of fibers was also enhanced by adding NC to the blend. Moreover, the washing and light fastness, and staining on cotton and wool for all blend and blend nanocomposites were acceptable for textile fibers. The linear density of PP was enhanced slightly when 10 wt.% PTT was added. Further enhancements were observed by adding NC to the PP/PTT blend. However, PP shrinkage was decreased by incorporating PTT and NC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

356. ALSE LAYER SYNDROME IN A COMMERCIAL LAYER FLOCK ASSOCIATED WITH INFECTIOUS BRONCHITIS VIRUS VARIANT.

Author

Shoushtari, Hamid and Motamed, Najmeh

Subjects
AVIAN infectious bronchitis virus, VIRUS diseases, BACTERIAL diseases, OVIDUCT, SYNDROMES
Abstract

False Layer Syndrome is a permanent condition that prevents hens from laying eggs as a consequence of early infectious bronchitis (IB) virus infection. Cystic oviduct associated with the reduced peak of egg production in apparently healthy layer flock was diagnosed. Considering the flock history different viral and bacteriological tests were done. Any evidence of bacterial infection was not found. IB virus (IBV) was detected in caecal tonsil samples, suggesting early IB virus infection, an isolated virus phylogenetically belonging to the Variant 2 genotype. However, it is the first report of a Variant 2 genotype causing cystic oviducts in Iran, complementary studies are needed to investigate the pathogenicity of these viruses for oviduct and their ability to develop cystic oviducts. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

357. Central neurocytomas: research trends, most cited papers, and scientometrics analysis to date.

Author

Durrani, Sulaman, Tebha, Sameer Saleem, Qamar, Mohammad Aadil, Nathani, Karim Rizwan, Harrison, Daniel Jeremiah, Aljameey, Usama A., Jarrah, Ryan, Shoushtari, Ali, and Bydon, Mohamad

Abstract

Central neurocytoma is the most common primary intraventricular tumor in adults being classified by the World Health Organization (WHO) as a benign grade II tumor with a good prognosis. Given the recent advances with regard to this tumor, a bibliometric analysis was due to study the future direction of research for neurocytomas. A comprehensive Elsevier’s Scopus database search was performed to capture all published and indexed studies to date relevant to neurocytoma. A discrete set of validated bibliometric parameters were extracted and analyzed on R v4.1.3. A total of 1002 documents were included in our analysis covering a period between 1910 and 2021 (111 years). Around 98.5% of the documents were multi-author publications with a collaboration index (CI) of 4.21. Acta Neuropathologica, The American Journal of Surgical Pathology, and Cancer were the journals to include the highest number of top ten cited articles (2 out of 10 most cited articles, 20%). Switzerland (4 out of 10, 40%) accounted for the country to have the highest number of top 10 most cited articles with the USA (5588 out of 16,395 citations, 34.1%) having the greatest number of citations. Lastly, our analysis reported an annual growth rate of 6.9% for the number of papers produced by year. This is the first bibliometric analysis to study the top 10 most cited articles with regard to neurocytomas. A shift from histopathologic and clinical symptoms towards the treatment and management of the tumor was observed in our analysis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

358. Mucosal Melanoma

Author

Henderson, Michael A., primary, Balch, Charles M., additional, Garbe, Claus, additional, Shoushtari, Alexander N., additional, Lian, Bin, additional, Cui, Chuanliang, additional, and Guo, Jun, additional

Published
2019
Full Text
View/download PDF

361. Patient experience with chronic obstructive pulmonary disease: a nationally representative demonstration study on quality and cost of healthcare services

Author

Ghamari, Seyyed-Hadi, Mohebi, Farnam, Abbasi-Kangevari, Mohsen, Peiman, Soheil, Rahimi, Besharat, Ahmadi, Naser, Farzi, Yousef, Seyfi, Shahedeh, Shahbal, Nazila, Modirian, Mitra, Azmin, Mehrdad, Zokaei, Hossein, Khezrian, Maryam, Sherafat, Roya, Malekpour, Mohammad-Reza, Roshani, Shahin, Rezaei, Negar, Fallahi, Mohammad Javad, Shoushtari, Maryam Haddadzadeh, Akbaripour, Zahra, Khatibzadeh, Shahab, and Shahraz, Saeid

Subjects
Public Health, Environmental and Occupational Health
Published
2023
Full Text
View/download PDF

362. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma:A phase 1 study

Author

Hamid, Omid, Hassel, Jessica C., Shoushtari, Alexander N., Meier, Friedegund, Bauer, Todd M., Salama, April K.S., Kirkwood, John M., Ascierto, Paolo A., Lorigan, Paul C., Mauch, Cornelia, Orloff, Marlana, Evans, Thomas R.Jeffry, Holland, Chris, Edukulla, Ramakrishna, Abedin, Shaad E., and Middleton, Mark R.

Subjects
T-Lymphocytes, Immunotherapy, Immune Checkpoint Inhibitors, Melanoma
Abstract

Background Immune checkpoint inhibitors have significantly improved outcomes in first line cutaneous melanoma. However, there is a high unmet need for patients who progress on these therapies and combination therapies are being explored to improve outcomes. Tebentafusp is a first-in-class gp100×CD3 ImmTAC bispecific that demonstrated overall survival (OS) benefit (HR 0.51) in metastatic uveal melanoma despite a modest overall response rate of 9%. This phase 1b trial evaluated the safety and initial efficacy of tebentafusp in combination with durvalumab (anti-programmed death ligand 1 (PDL1)) and/or tremelimumab (anti-cytotoxic T lymphocyte-associated antigen 4) in patients with metastatic cutaneous melanoma (mCM), the majority of whom progressed on prior checkpoint inhibitors. Methods In this open-label, multicenter, phase 1b, dose-escalation trial, HLA-A∗02:01-positive patients with mCM received weekly intravenous tebentafusp with increasing monthly doses of durvalumab and/or tremelimumab starting day 15 of each cycle. The primary objective was to identify the maximum tolerated dose (MTD) or recommended phase 2 dose for each combination. Efficacy analyses were performed in all tebentafusp with durvalumab±tremelimumab treated patients with a sensitivity analysis in those who progressed on prior anti-PD(L)1 therapy. Results 85 patients were assigned to receive tebentafusp in combination with durvalumab (n=43), tremelimumab (n=13), or durvalumab and tremelimumab (n=29). Patients were heavily pretreated with a median of 3 prior lines of therapy, including 76 (89%) who received prior anti-PD(L)1. Maximum target doses of tebentafusp (68 mcg) alone or in combination with durvalumab (20 mg/kg) and tremelimumab (1 mg/kg) were tolerated; MTD was not formally identified for any arm. Adverse event profile was consistent with each individual therapy and there were no new safety signals nor treatment-related deaths. In the efficacy subset (n=72), the response rate was 14%, tumor shrinkage rate was 41% and 1-year OS rate was 76% (95% CI: 70% to 81%). The 1-year OS for triplet combination (79%; 95% CI: 71% to 86%) was similar to tebentafusp plus durvalumab (74%; 95% CI: 67% to 80%). Conclusion At maximum target doses, the safety of tebentafusp with checkpoint inhibitors was consistent with safety of each individual therapy. Tebentafusp with durvalumab demonstrated promising efficacy in heavily pretreated patients with mCM, including those who progressed on prior anti-PD(L)1. Trial registration number NCT02535078.

Published
2023

363. New records of two noctuid species (Lepidoptera, Noctuidae) from Iran

Author

Moghadaszadeh Kermani, Melika, Poorshabanan, Pedram, Dehlaghi, Ehsan, Shirvani, Asghar, and Vafaei Shoushtari, Reza

Subjects
taxonomy, distribution, Dichagyris, Leucochlaena, fauna
Abstract

The biodiversity of the Noctuidae, an economically important family of Noctuoidea which include major crop pests, is becoming well-identified nowadays in Iran due to the increased number of faunal expeditions. The two large subfamilies of Noctuidae namely Xyleninae Guenée, 1837 and Noctuinae Latreille, 1809 comprise the majority of Iran's noctuid moth fauna. Two species,Leucochlaena hoerhammeri(Wagner, 1931) andDichagyris(Stenosomides)mansoura(Chrétien, 1911) members of Xyleninae and Noctuinae subfamilies, respectively, are recorded from Iran for the first time. This is also the first record of the subgenusStenosomidesStrand, 1942from Iran.Both the external and genital characteristics of the newly recorded species are presented together with illustrations of the adults and their genitalia.

Published
2023

364. Block Coordinate Plug-and-Play Methods for Blind Inverse Problems

Author

Gan, Weijie, Shoushtari, Shirin, Hu, Yuyang, Liu, Jiaming, An, Hongyu, and Kamilov, Ulugbek S.

Subjects
FOS: Computer and information sciences, Computer Science - Machine Learning, Computer Vision and Pattern Recognition (cs.CV), Image and Video Processing (eess.IV), FOS: Electrical engineering, electronic engineering, information engineering, Computer Science - Computer Vision and Pattern Recognition, Electrical Engineering and Systems Science - Image and Video Processing, Machine Learning (cs.LG)
Abstract

Plug-and-play (PnP) prior is a well-known class of methods for solving imaging inverse problems by computing fixed-points of operators combining physical measurement models and learned image denoisers. While PnP methods have been extensively used for image recovery with known measurement operators, there is little work on PnP for solving blind inverse problems. We address this gap by presenting a new block-coordinate PnP (BC-PnP) method that efficiently solves this joint estimation problem by introducing learned denoisers as priors on both the unknown image and the unknown measurement operator. We present a new convergence theory for BC-PnP compatible with blind inverse problems by considering nonconvex data-fidelity terms and expansive denoisers. Our theory analyzes the convergence of BC-PnP to a stationary point of an implicit function associated with an approximate minimum mean-squared error (MMSE) denoiser. We numerically validate our method on two blind inverse problems: automatic coil sensitivity estimation in magnetic resonance imaging (MRI) and blind image deblurring. Our results show that BC-PnP provides an efficient and principled framework for using denoisers as PnP priors for jointly estimating measurement operators and images.

Published
2023

367. Dynamic Walking with a Soft Limb Robot

Author

Ansari, Yasmin, Shoushtari, Ali Leylavi, Cacucciolo, Vito, Cianchetti, Matteo, Laschi, Cecilia, Goebel, Randy, Series editor, Tanaka, Yuzuru, Series editor, Wahlster, Wolfgang, Series editor, Wilson, Stuart P., editor, Verschure, Paul F.M.J., editor, Mura, Anna, editor, and Prescott, Tony J., editor

Published
2015
Full Text
View/download PDF

374. Technical note: Analysis of claims and disputes in contracts for oil and gas development projects in Iran with solutions

Author

Fathollah Sajedi and Farrokh Sarmast Shoushtari

Subjects
factor, claim, dispute, solution, oil and gas contracts, iran, Bridge engineering, TG1-470, Building construction, TH1-9745
Abstract

Contracts for oil and gas development projects are naturally complex, they are explained with some of maps and technical specifications. To supply the goals of contracts, it is necessary to construct by a team having owner, consulting engineer and contractor. The unique aspects of each project and team working are resulting to disagreements. It should be noted that the majority of team workers have not previously worked together. It may not be expected to forecast all project aspects in design and preparation of tender documents process. However, in some cases it will occur inconsistencies in contract documents and possibly may be disagreements on commentary of the cases which there are in the provisions of the contract. Every root of disagreement resulted in to claim and finally dispute. Lack of foresight and/or existing ambiguous texts in some provisions of contract, not being aware of components of the project to conditions and obligations and rules of contract will complex and sometimes impossible the agreement on implementation problems. Therefore, the claims will be resulted in disputes and inflict financial losses to contractors and/or owners and then the projects will not be completed. In Iran many activities have not been carried out about claims and disputes in different orientations especially in areas futures and hence, it was studied in this research. Firstly, research history was considered and the causes of claims and disputes were identified in process of different levels of oil projects construction from primary to exploitation and then a questionnaire was prepared using the comments of experts. Finally, the questionnaire was analysed by SPSS and the approved factors in creation of claims and disputes and in their roots were ranked.

Published
2017
Full Text
View/download PDF

375. Machine Learning Models to Predict In-Hospital Mortality among Inpatients with COVID-19: Underestimation and Overestimation Bias Analysis in Subgroup Populations

Author

Javad Zarei, Amir Jamshidnezhad, Maryam Haddadzadeh Shoushtari, Ali Mohammad Hadianfard, Maria Cheraghi, and Abbas Sheikhtaheri

Subjects
Machine Learning, Inpatients, ROC Curve, Article Subject, Biomedical Engineering, COVID-19, Humans, Health Informatics, Surgery, Hospital Mortality, Biotechnology
Abstract

Prediction of the death among COVID-19 patients can help healthcare providers manage the patients better. We aimed to develop machine learning models to predict in-hospital death among these patients. We developed different models using different feature sets and datasets developed using the data balancing method. We used demographic and clinical data from a multicenter COVID-19 registry. We extracted 10,657 records for confirmed patients with PCR or CT scans, who were hospitalized at least for 24 hours at the end of March 2021. The death rate was 16.06%. Generally, models with 60 and 40 features performed better. Among the 240 models, the C5 models with 60 and 40 features performed well. The C5 model with 60 features outperformed the rest based on all evaluation metrics; however, in external validation, C5 with 32 features performed better. This model had high accuracy (91.18%), F-score (0.916), Area under the Curve (0.96), sensitivity (94.2%), and specificity (88%). The model suggested in this study uses simple and available data and can be applied to predict death among COVID-19 patients. Furthermore, we concluded that machine learning models may perform differently in different subpopulations in terms of gender and age groups.

Published
2022

379. Abstract CT223: Long-term survival follow-up of tebentafusp in previously treated metastatic uveal melanoma (mUM)

Author

Sacco, Joseph J., primary, Carvajal, Richard D., additional, Butler, Marcus O., additional, Shoushtari, Alexander N., additional, Hassel, Jessica C., additional, Ikeguchi, Alexandra, additional, Hernandez-Aya, Leonel, additional, Nathan, Paul, additional, Hamid, Omid, additional, Piulats, Josep M., additional, Rioth, Matthew, additional, Johnson, Douglas B., additional, Luke, Jason J., additional, Espinosa, Erique, additional, Leyvraz, Serge, additional, Collins, Laura, additional, Holland, Chris, additional, McCully, Michelle L., additional, and Sato, Takami, additional

Published
2023
Full Text
View/download PDF

381. Data from Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis

Author

Li, Jun, primary, Duran, Mercedes A., primary, Dhanota, Ninjit, primary, Chatila, Walid K., primary, Bettigole, Sarah E., primary, Kwon, John, primary, Sriram, Roshan K., primary, Humphries, Matthew P., primary, Salto-Tellez, Manuel, primary, James, Jacqueline A., primary, Hanna, Matthew G., primary, Melms, Johannes C., primary, Vallabhaneni, Sreeram, primary, Litchfield, Kevin, primary, Usaite, Ieva, primary, Biswas, Dhruva, primary, Bareja, Rohan, primary, Li, Hao Wei, primary, Martin, Maria Laura, primary, Dorsaint, Princesca, primary, Cavallo, Julie-Ann, primary, Li, Peng, primary, Pauli, Chantal, primary, Gottesdiener, Lee, primary, DiPardo, Benjamin J., primary, Hollmann, Travis J., primary, Merghoub, Taha, primary, Wen, Hannah Y., primary, Reis-Filho, Jorge S., primary, Riaz, Nadeem, primary, Su, Shin-San Michael, primary, Kalbasi, Anusha, primary, Vasan, Neil, primary, Powell, Simon N., primary, Wolchok, Jedd D., primary, Elemento, Olivier, primary, Swanton, Charles, primary, Shoushtari, Alexander N., primary, Parkes, Eileen E., primary, Izar, Benjamin, primary, and Bakhoum, Samuel F., primary

Published
2023
Full Text
View/download PDF

382. Supplementary Tables 1-3 and Supplementary Figures 1-4 from Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071

Author

Piperno-Neumann, Sophie, primary, Larkin, James, primary, Carvajal, Richard D., primary, Luke, Jason J., primary, Schwartz, Gary K., primary, Hodi, F. Stephen, primary, Sablin, Marie-Paule, primary, Shoushtari, Alexander N., primary, Szpakowski, Sebastian, primary, Chowdhury, Niladri Roy, primary, Brannon, A. Rose, primary, Ramkumar, Thiruvamoor, primary, de Koning, Leanne, primary, Derti, Adnan, primary, Emery, Caroline, primary, Yerramilli-Rao, Padmaja, primary, and Kapiteijn, Ellen, primary

Published
2023
Full Text
View/download PDF

383. Supplementary Data PDF from Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis

Author

Li, Jun, primary, Duran, Mercedes A., primary, Dhanota, Ninjit, primary, Chatila, Walid K., primary, Bettigole, Sarah E., primary, Kwon, John, primary, Sriram, Roshan K., primary, Humphries, Matthew P., primary, Salto-Tellez, Manuel, primary, James, Jacqueline A., primary, Hanna, Matthew G., primary, Melms, Johannes C., primary, Vallabhaneni, Sreeram, primary, Litchfield, Kevin, primary, Usaite, Ieva, primary, Biswas, Dhruva, primary, Bareja, Rohan, primary, Li, Hao Wei, primary, Martin, Maria Laura, primary, Dorsaint, Princesca, primary, Cavallo, Julie-Ann, primary, Li, Peng, primary, Pauli, Chantal, primary, Gottesdiener, Lee, primary, DiPardo, Benjamin J., primary, Hollmann, Travis J., primary, Merghoub, Taha, primary, Wen, Hannah Y., primary, Reis-Filho, Jorge S., primary, Riaz, Nadeem, primary, Su, Shin-San Michael, primary, Kalbasi, Anusha, primary, Vasan, Neil, primary, Powell, Simon N., primary, Wolchok, Jedd D., primary, Elemento, Olivier, primary, Swanton, Charles, primary, Shoushtari, Alexander N., primary, Parkes, Eileen E., primary, Izar, Benjamin, primary, and Bakhoum, Samuel F., primary

Published
2023
Full Text
View/download PDF

387. Supplementary Figures S1 to S7 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma

Author

Shoushtari, Alexander N., primary, Olszanski, Anthony J., primary, Nyakas, Marta, primary, Hornyak, Thomas J., primary, Wolchok, Jedd D., primary, Levitsky, Victor, primary, Kuryk, Lukasz, primary, Hansen, Thomas B., primary, and Jäderberg, Magnus, primary

Published
2023
Full Text
View/download PDF

389. Figure S1 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

Author

Shoushtari, Alexander N., primary, Chatila, Walid K., primary, Arora, Arshi, primary, Sanchez-Vega, Francisco, primary, Kantheti, Havish S., primary, Rojas Zamalloa, Jorge A., primary, Krieger, Penina, primary, Callahan, Margaret K., primary, Betof Warner, Allison, primary, Postow, Michael A., primary, Momtaz, Parisa, primary, Nair, Suresh, primary, Ariyan, Charlotte E., primary, Barker, Christopher A., primary, Brady, Mary Susan, primary, Coit, Daniel G., primary, Rosen, Neal, primary, Chapman, Paul B., primary, Busam, Klaus J., primary, Solit, David B., primary, Panageas, Katherine S., primary, Wolchok, Jedd D., primary, and Schultz, Nikolaus, primary

Published
2023
Full Text
View/download PDF

390. Supplementary Data from Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma

Author

Middleton, Mark R., primary, McAlpine, Cheryl, primary, Woodcock, Victoria K., primary, Corrie, Pippa, primary, Infante, Jeffrey R., primary, Steven, Neil M., primary, Evans, Thomas R. Jeffry, primary, Anthoney, Alan, primary, Shoushtari, Alexander N., primary, Hamid, Omid, primary, Gupta, Avinash, primary, Vardeu, Antonella, primary, Leach, Emma, primary, Naidoo, Revashnee, primary, Stanhope, Sarah, primary, Lewis, Sion, primary, Hurst, Jacob, primary, O’Kelly, Ita, primary, and Sznol, Mario, primary

Published
2023
Full Text
View/download PDF

391. Supplementary Tables S1-S11 from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma

Author

Hitchman, Tyler D., primary, Bayshtok, Gabriella, primary, Ceraudo, Emilie, primary, Moore, Amanda R., primary, Lee, Cindy, primary, Jia, Ruobing, primary, Wang, Naitao, primary, Pachai, Mohini R., primary, Shoushtari, Alexander N., primary, Francis, Jasmine H., primary, Guan, Youxin, primary, Chen, Juliet, primary, Chang, Matthew T., primary, Taylor, Barry S., primary, Sakmar, Thomas P., primary, Huber, Thomas, primary, Chi, Ping, primary, and Chen, Yu, primary

Published
2023
Full Text
View/download PDF

392. Supplementary Figure S7 from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma

Author

Hitchman, Tyler D., primary, Bayshtok, Gabriella, primary, Ceraudo, Emilie, primary, Moore, Amanda R., primary, Lee, Cindy, primary, Jia, Ruobing, primary, Wang, Naitao, primary, Pachai, Mohini R., primary, Shoushtari, Alexander N., primary, Francis, Jasmine H., primary, Guan, Youxin, primary, Chen, Juliet, primary, Chang, Matthew T., primary, Taylor, Barry S., primary, Sakmar, Thomas P., primary, Huber, Thomas, primary, Chi, Ping, primary, and Chen, Yu, primary

Published
2023
Full Text
View/download PDF

393. Table S1 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

Author

Shoushtari, Alexander N., primary, Chatila, Walid K., primary, Arora, Arshi, primary, Sanchez-Vega, Francisco, primary, Kantheti, Havish S., primary, Rojas Zamalloa, Jorge A., primary, Krieger, Penina, primary, Callahan, Margaret K., primary, Betof Warner, Allison, primary, Postow, Michael A., primary, Momtaz, Parisa, primary, Nair, Suresh, primary, Ariyan, Charlotte E., primary, Barker, Christopher A., primary, Brady, Mary Susan, primary, Coit, Daniel G., primary, Rosen, Neal, primary, Chapman, Paul B., primary, Busam, Klaus J., primary, Solit, David B., primary, Panageas, Katherine S., primary, Wolchok, Jedd D., primary, and Schultz, Nikolaus, primary

Published
2023
Full Text
View/download PDF

394. Supplemental Methods from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Author

Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary

Published
2023
Full Text
View/download PDF

395. Supplemental Table 4 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Author

Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary

Published
2023
Full Text
View/download PDF

396. Supplemental Figure 2 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Author

Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary

Published
2023
Full Text
View/download PDF

397. Supplemental Table 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Author

Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary

Published
2023
Full Text
View/download PDF

398. Supplementary Figures S1-S6 from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma

Author

Hitchman, Tyler D., primary, Bayshtok, Gabriella, primary, Ceraudo, Emilie, primary, Moore, Amanda R., primary, Lee, Cindy, primary, Jia, Ruobing, primary, Wang, Naitao, primary, Pachai, Mohini R., primary, Shoushtari, Alexander N., primary, Francis, Jasmine H., primary, Guan, Youxin, primary, Chen, Juliet, primary, Chang, Matthew T., primary, Taylor, Barry S., primary, Sakmar, Thomas P., primary, Huber, Thomas, primary, Chi, Ping, primary, and Chen, Yu, primary

Published
2023
Full Text
View/download PDF

399. Supplementary Data from Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer

Author

Hanrahan, Aphrothiti J., primary, Sylvester, Brooke E., primary, Chang, Matthew T., primary, Elzein, Arijh, primary, Gao, Jianjiong, primary, Han, Weiwei, primary, Liu, Ye, primary, Xu, Dong, primary, Gao, Sizhi P., primary, Gorelick, Alexander N., primary, Jones, Alexis M., primary, Kiliti, Amber J., primary, Nissan, Moriah H., primary, Nimura, Clare A., primary, Poteshman, Abigail N., primary, Yao, Zhan, primary, Gao, Yijun, primary, Hu, Wenhuo, primary, Wise, Hannah C., primary, Gavrila, Elena I., primary, Shoushtari, Alexander N., primary, Tiwari, Shakuntala, primary, Viale, Agnes, primary, Abdel-Wahab, Omar, primary, Merghoub, Taha, primary, Berger, Michael F., primary, Rosen, Neal, primary, Taylor, Barry S., primary, and Solit, David B., primary

Published
2023
Full Text
View/download PDF

400. Supplemental Figure 3 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Author

Postow, Michael A., primary, Knox, Susan J., primary, Goldman, Debra A., primary, Elhanati, Yuval, primary, Mavinkurve, Vikram, primary, Wong, Phillip, primary, Halpenny, Darragh, primary, Reddy, Sunil K., primary, Vado, Kenya, primary, McCabe, Danielle, primary, Ramirez, Kristen Aufiero, primary, Macri, Mary, primary, Schwarzenberger, Paul, primary, Ricciardi, Toni, primary, Ryan, Aileen, primary, Venhaus, Ralph, primary, Momtaz, Parisa, primary, Shoushtari, Alexander N., primary, Callahan, Margaret K., primary, Chapman, Paul B., primary, Wolchok, Jedd D., primary, Subrahmanyam, Priyanka B., primary, Maecker, Holden T., primary, Panageas, Katherine S., primary, and Barker, Christopher A., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results